Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorPeking University People's Hospital
About this trial
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Eligibility criteria
Qualifiers
Male or female, aged between 18-65 years;
PLT<20×10^9/L or transfusion dependent on +D7 after haplo-HSCT;
Agree to receive the treatment of avatrombopag after Haplo-HSCT and sign the informed consent form.
Disqualifiers
With active infection;
ALT or AST>3ULN, or total Bil>2ULN
Ccr<50 mL/min;
With the history of arteriovenous thrombosis;
Trial design
Treatments tested in this trial
- avatrombopag
- Placebo
Treatment groups
142 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking University People's Hospital
Lead sponsor
Xiangya Hospital of Central South University
Collaborator
Sichuan Provincial People's Hospital
Collaborator
First Affiliated Hospital of Harbin Medical University
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
First Affiliated Hospital of Xinjiang Medical University
Collaborator
Shanxi Bethune Hospital
Collaborator
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Collaborator
Tang-Du Hospital
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator
Source ClinicalTrials.gov